eFFECTOR Therapeutics, Inc.

70 articles about eFFECTOR Therapeutics, Inc.

• eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

  9/11/2023

  eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board’s Audit Committee.

• eFFECTOR Therapeutics to Participate in Upcoming September 2023 Investor Conferences

  8/30/2023

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences.

• eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/8/2023

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings

  6/8/2023

  eFFECTOR Therapeutics, Inc. announced that it has closed its previously announced $8.7 million registered direct offering for the purchase and sale of an aggregate of 7,764,445 shares of its common stock, at a purchase price of $1.125 per share, priced at-the-market under Nasdaq rules.

• eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  6/7/2023

  eFFECTOR Therapeutics, Inc. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 7,764,445 shares of its common stock.

• eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  5/26/2023

  eFFECTOR Therapeutics, Inc. announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of an aggregate of 11,450,382 shares of its common stock, at a purchase price of $0.655 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

• eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting

  5/25/2023

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced positive interim data updates from a Phase 2 expansion cohort evaluating zotatifin combined with fulvestrant and abemaciclib in patients with ER+ metastatic breast cancer.

• eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/9/2023

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference - May 08, 2023

  5/8/2023

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the JMP Securities Life Sciences Conference taking place May 15-16, 2023 in New York, NY.

• eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual MeetingeFFECTOR to host conference call following ASCO presentation

  4/26/2023

  eFFECTOR Therapeutics, Inc. announced a poster highlighting results from Phase 2 expansion cohorts of a Phase 1/2 dose escalation and expansion trial with zotatifin in patients with ER+ Metastatic Breast Cancer has been selected for presentation at the American Society of Clinical Oncology 2023 Annual Meeting.

• eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer

  4/11/2023

  eFFECTOR Therapeutics, Inc. announced a clinical collaboration with Jennifer Caswell-Jin, M.D., Assistant Professor of Medicine at Stanford Medicine, who will serve as principal investigator in an investigator-initiated trial evaluating zotatifin in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in a pre-operative setting.

• eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - March 28, 2023

  3/28/2023

  eFFECTOR Therapeutics, Inc. today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences.

• eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/8/2023

  eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a corporate update.

• eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVIDResults presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI)

  2/21/2023

  eFFECTOR Therapeutics, Inc. today announced top-line results from its Phase 1b clinical trial of zotatifin for the treatment of COVID demonstrating favorable safety results as well as positive trends in several measures of antiviral activity.

• eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference

  1/30/2023

  eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, announced that the Company will present and host 1x1 meetings at the 2023 BIO CEO & Investor Conference from February 6-9, 2023 in New York City, NY.

• eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

  1/5/2023

  eFFECTOR Therapeutics, Inc. provided an update on its ongoing clinical development programs for both zotatifin, in Phase 2 expansion cohorts for the treatment of estrogen receptor positive breast cancer and KRAS non-small cell lung cancer as well as Phase 1 development for SARS-CoV-2, and tomivosertib, in a Phase 2b trial for the treatment of non-small cell lung cancer in combination with pembrolizumab, an established anti-immune checkpoint inhibitor used to treat various types of cancer.

• eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/7/2022

  eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

  10/31/2022

  eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that the management team will participate in and host 1x1 meetings at the following upcoming investor conferences.

• eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19

  10/26/2022

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced it has completed enrollment for the second cohort of a three cohort Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection.

• eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

  9/26/2022

  eFFECTOR Therapeutics, Inc. today announced it has appointed Mayank J. Gandhi, M.D., as chief business officer.